Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd. (SLGL): 2 pipeline candidates · 5 upcoming catalysts · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
N/A
D/E 0.31 · 0% dilution
Lead: Phase 3
2 candidates
5 upcoming, next in ~44d
18 buys · 0 sells (180d)
A transparent, data-derived signal for Sol-Gel Technologies Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$241.1M
Cash
$12.2M
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| patidegib | Phase 3 |
| patidegib topical gel with no active patidegib | Phase 3 |
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$29.9M
| Holder | Shares | Value |
|---|---|---|
| great point partners llc | 274,363 | $21.7M |
| citadel advisors llc | 37,145 | $2.9M |
| affinity asset advisors, llc | 35,000 | $2.8M |
| xtx topco ltd | 8,010 | $635K |
| jane street group, llc | 7,152 | $567K |
| raymond james financial inc | 5,733 | $454K |
| morgan stanley | 5,171 | $410K |
| lpl financial llc | 3,469 | $275K |
| blackrock, inc. | 953 | $75K |
| ubs group ag | 694 | $55K |
Showing top 10 of 14 institutional holders of Sol-Gel Technologies Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Sol-Gel Technologies Ltd.'s pipeline?
Sol-Gel Technologies Ltd. (SLGL) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Sol-Gel Technologies Ltd.'s lead drug candidate?
Sol-Gel Technologies Ltd.'s most advanced tracked candidate is patidegib (Phase 3) for Gorlin Syndrome.
What is Sol-Gel Technologies Ltd.'s next catalyst?
Sol-Gel Technologies Ltd.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Pa" — expected August 1, 2026.
What is Sol-Gel Technologies Ltd.'s market capitalization?
Sol-Gel Technologies Ltd.'s market capitalization is approximately $241.1M.
Who is the CEO of Sol-Gel Technologies Ltd.?
Mr. Moshe Arkin is the chief executive officer of Sol-Gel Technologies Ltd. (SLGL).
Get the full picture on Sol-Gel Technologies Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.